The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...

Johnson & Johnson has announced that its Darzalex Faspro-based regimen (daratumumab and hyaluronidase, in combination with ...

Tecvayli monotherapy significantly reduces disease progression and mortality in relapsed or refractory multiple myeloma patients, showing a 71% reduction in progression risk and 40% in mortality risk.

D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...

Darzalex Faspro is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase.

Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...

Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Smoldering multiple myeloma is a complex, intermediary stage ...